Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Studying the Patient/Caregiver Lived Experience in Dementia with Lewy Bodies
Cognition Therapeutics (NASDAQ: CGTX) has released its tenth episode of the "Conversations" video podcast series focused on Dementia with Lewy Bodies (DLB). The two-part episode features caregivers Carla Preyer and Linda Szypula Ed.D., who were previously featured in the documentary "Facing the Wind," alongside medical experts Dr. Brendan Kelley from UT Southwestern Medical Center and Dr. Samantha K. Holden from the University of Colorado School of Medicine.
Part 1 explores caregiver challenges and distress in managing DLB patients, while Part 2 discusses the disease's fluctuating symptoms and measurement tools. The episode also provides insights into meaningful symptoms for patients and families, and how this information guides DLB clinical trial design.
Cognition Therapeutics (NASDAQ: CGTX) ha pubblicato il decimo episodio della serie di video podcast "Conversations" dedicata alla Demenza a Corpi di Lewy (DLB). L'episodio, suddiviso in due parti, presenta le testimonianze delle caregiver Carla Preyer e Linda Szypula Ed.D., già protagoniste del documentario "Facing the Wind", insieme agli esperti medici Dr. Brendan Kelley del UT Southwestern Medical Center e Dr. Samantha K. Holden della University of Colorado School of Medicine.
La prima parte affronta le difficoltà e lo stress vissuti dai caregiver nella gestione dei pazienti con DLB, mentre la seconda parte si concentra sui sintomi fluttuanti della malattia e sugli strumenti di valutazione. L'episodio offre inoltre approfondimenti sui sintomi significativi per pazienti e famiglie e su come queste informazioni orientino la progettazione degli studi clinici sulla DLB.
Cognition Therapeutics (NASDAQ: CGTX) ha lanzado el décimo episodio de la serie de videopodcasts "Conversations" centrada en la Demencia con Cuerpos de Lewy (DLB). El episodio, dividido en dos partes, presenta a las cuidadoras Carla Preyer y Linda Szypula Ed.D., quienes ya participaron en el documental "Facing the Wind", junto con los expertos médicos Dr. Brendan Kelley del UT Southwestern Medical Center y Dr. Samantha K. Holden de la University of Colorado School of Medicine.
La primera parte explora los retos y el estrés que enfrentan los cuidadores al atender a pacientes con DLB, mientras que la segunda aborda los síntomas fluctuantes de la enfermedad y las herramientas para su medición. Además, el episodio ofrece perspectivas sobre los síntomas significativos para pacientes y familias, y cómo esta información guía el diseño de ensayos clínicos para la DLB.
Cognition Therapeutics (NASDAQ: CGTX)는 루이체 치매(DLB)를 주제로 한 'Conversations' 비디오 팟캐스트 시리즈의 열 번째 에피소드를 공개했습니다. 두 부분으로 구성된 이번 에피소드에는 다큐멘터리 'Facing the Wind'에 출연했던 간병인 Carla Preyer와 Linda Szypula Ed.D., 그리고 UT Southwestern Medical Center의 Dr. Brendan Kelley와 University of Colorado School of Medicine의 Dr. Samantha K. Holden 의료 전문가가 함께 참여했습니다.
1부에서는 DLB 환자를 돌보는 간병인들의 어려움과 스트레스에 대해 다루며, 2부에서는 질병의 변동성 있는 증상과 측정 도구에 대해 논의합니다. 또한 이번 에피소드는 환자와 가족에게 중요한 증상과 이러한 정보가 DLB 임상시험 설계에 어떻게 반영되는지에 대한 통찰도 제공합니다.
Cognition Therapeutics (NASDAQ: CGTX) a publié le dixième épisode de sa série de vidéopodcasts "Conversations" axée sur la démence à corps de Lewy (DLB). Cet épisode en deux parties met en vedette les aidantes Carla Preyer et Linda Szypula Ed.D., déjà présentées dans le documentaire "Facing the Wind", ainsi que les experts médicaux Dr. Brendan Kelley du UT Southwestern Medical Center et Dr. Samantha K. Holden de l'University of Colorado School of Medicine.
La première partie explore les défis et le stress rencontrés par les aidants dans la prise en charge des patients atteints de DLB, tandis que la deuxième partie aborde les symptômes fluctuants de la maladie et les outils de mesure. L'épisode offre également des perspectives sur les symptômes significatifs pour les patients et leurs familles, ainsi que sur la manière dont ces informations guident la conception des essais cliniques sur la DLB.
Cognition Therapeutics (NASDAQ: CGTX) hat die zehnte Folge der Videopodcast-Reihe "Conversations" veröffentlicht, die sich auf die Demenz mit Lewy-Körpern (DLB) konzentriert. Die zweiteilige Folge zeigt die Pflegepersonen Carla Preyer und Linda Szypula Ed.D., die bereits im Dokumentarfilm "Facing the Wind" zu sehen waren, zusammen mit den medizinischen Experten Dr. Brendan Kelley vom UT Southwestern Medical Center und Dr. Samantha K. Holden von der University of Colorado School of Medicine.
Teil 1 behandelt die Herausforderungen und Belastungen von Pflegepersonen bei der Betreuung von DLB-Patienten, während Teil 2 die schwankenden Symptome der Krankheit und die Messinstrumente bespricht. Die Folge bietet außerdem Einblicke in für Patienten und Familien bedeutsame Symptome und wie diese Informationen die Gestaltung klinischer Studien zu DLB beeinflussen.
- None.
- None.
PURCHASE, N.Y., May 28, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, has released its tenth Conversations video podcast episode: “Studying the Patient/Caregiver Lived Experience in Dementia with Lewy Bodies.”
This two-part conversation spotlights two caregivers who were featured in the documentary, Facing the Wind*. In the documentary, they discussed their personal experiences with Lewy body dementia, how the disease affected their loved ones, and how they coped with caring for them.
- Carla Preyer, salon owner, inspirational speaker and care partner to her husband, Patrick
- Linda Szypula Ed.D., science teacher and care partner to her husband, James
Ms. Preyer and Ms. Szypula are joined by two physician experts in memory and movement disorders who also participated as investigators in Cognition’s Phase 2 ‘SHIMMER’ DLB study. In Part 1: they review the challenges of caring for someone with DLB and the distress it can cause for caregivers themselves. In Part 2: they consider the fluctuating symptoms of this disease and the tools available to measure them. Caregivers also provide insight into the symptoms they consider most meaningful to both patients and their families, and physicians discuss how this information informs the design of clinical trials for DLB.
- Brendan Kelley, M.D., professor and clinical vice chair in the department of neurology at the University of Texas Southwestern Medical Center
- Samantha K. Holden, MD, MS, FAAN, associate professor of neurology, vice chair for outpatient neurology services at the University of Colorado School of Medicine
Listen to Episode 10: Studying the Patient/Caregiver Lived Experience in Dementia with Lewy Bodies, on the Conversations tab of the Cognition Therapeutics website.
Health Care Disclaimer
Our podcast series does not constitute the practice of medical advice, diagnosis or treatment. Always talk to your health care provider for diagnosis and treatment, including your specific medical needs. If you have or suspect that you have a medical problem or condition, please contact a qualified health care professional immediately.
* Facing the Wind is a collaboration between award-winning director, Deirdre Fishel and producer, Tony Heriza. Information about the film and where it may be viewed is available at https://facingthewindfilm.com.
About the SHIMMER Study
The SHIMMER study (NCT05225415) is an exploratory double-blind, placebo-controlled Phase 2 clinical trial that enrolled 130 adults with mild-to-moderate DLB, who were randomized to either daily oral doses of zervimesine (100 mg or 300 mg) or placebo for six months. Assessments were conducted throughout the study using a number of tools, including the Neuropsychiatric Inventory (NPI) to measure changes in hallucinations, anxiety and delusions; the Clinician Assessment of Fluctuation (CAF) to measure the frequency and duration of cognitive fluctuations; the Montreal Cognitive Assessment (MoCA) and Cognitive Drug Research Battery (CDR), which track cognitive performance; and the MDS-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part III, an objective assessment of parkinsonism.
The SHIMMER study was supported by a grant award from the National Institute on Aging of the National Institutes of Health (NIH) totaling approximately
About Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc., is a clinical-stage biopharmaceutical company discovering and developing innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system. We are currently investigating our lead candidate, zervimesine (CT1812), in clinical programs in dementia with Lewy bodies (DLB) and Alzheimer’s disease, including the ongoing START study (NCT05531656) in early Alzheimer’s disease. We believe zervimesine can regulate pathways that are impaired in these diseases though its interaction with the sigma-2 receptor, a mechanism that is functionally distinct from other approaches for the treatment of degenerative diseases. More about Cognition Therapeutics and our pipeline can be found at https://cogrx.com.
| Contact Information: Cognition Therapeutics, Inc. info@cogrx.com | Casey McDonald (media) Tiberend Strategic Advisors, Inc. cmcdonald@tiberend.com | Mike Moyer (investors) LifeSci Advisors mmoyer@lifesciadvisors.com |
This press release was published by a CLEAR® Verified individual.
FAQ
What is the focus of Cognition Therapeutics' (CGTX) latest podcast episode?
Who are the featured guests in CGTX's new Conversations podcast episode?
What topics are covered in the two parts of CGTX's DLB podcast episode?
Where can investors find Cognition Therapeutics' latest podcast episode?
